SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,…
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in…
- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for…
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2…
Development Advisory Committee strengthened with the expertise and leadership of Dr. YavariTORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --…
Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:…
New migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression…
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) --…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers…
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access…